Clinical trialPhase 2Completed
Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer
A Phase II Study of Neoadjuvant Chemotherapy With and Without Immunotherapy to CA125 (Oregovomab) Followed by Hypofractionated Stereotactic Radiotherapy & Concurrent HIV Protease Inhibitor Nelfinavir in Locally Advanced Pancreatic Cancer
- Outcome
- Results posted; single-arm, no comparison
- Phase
- Phase 2
- Status
- Completed
- Study type
- Interventional
- Start
- 6 September 2013
- Ended
- 1 December 2018
- Enrollment
- 11 participants
- Sites
- 1
- Primary outcomes
- Number of Participants With Progressive Disease,
- Sponsor type
- Academic / other
- Results posted
- 15 November 2019
- Last update
- 10 October 2023
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Results
- Primary endpoint
- Results posted; single-arm, no comparisonAs posted on ClinicalTrials.gov ↗, registry record of 10 October 2023
- Primary outcome
- Number of Participants With Progressive Disease,Treatment (Chemotherapy, Oregovomab, SBRT, Surgery): 2 of 10Values: ParticipantsTime frame: Up to 4 monthsNo analysis posted for this outcome (outcome 1)
- Participants
- Treatment (Chemotherapy, Oregovomab, SBRT, Surgery): 11 started, 10 completed
- Serious adverse events
- Treatment (Chemotherapy, Oregovomab, SBRT, Surgery): 6 of 11Participants with at least one serious adverse event, of those at risk, as posted
4 secondary outcomes
- Distant Failure-free Survival
- Treatment (Chemotherapy, Oregovomab, SB… 11 (7 to 15), n=11 [median months, 95% Confidence Interval]
- OS · Overall Survival
- Treatment (Chemotherapy, Oregovomab, SB… 14.4 (12 to 18), n=11 [median months, 95% Confidence Interval]
- Surgical Complete Resection (Negative Margin) Rate
- Treatment (Chemotherapy, Oregovomab, SB… 4/10 [Participants]
- Tumor Response Rate, Evaluated on the Pathology Specimen
- Pathologic poor response: Treatment (Chemotherapy, Oregovomab, SB… 2/4 [Participants] (first of 3 rows)
Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This phase II trial studies how well combination chemotherapy with or without oregovomab followed by stereotactic body radiation therapy (SBRT) and nelfinavir mesylate works in treating patients with pancreatic cancer that has spread to nearby organs or tissues. Drugs used in chemotherapy, such as gemcitabine hydrochloride, leucovorin calcium, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as oregovomab, can block tumor growth in different ways by targeting certain cells. Stereotactic body radiation therapy is a specialized radiation therapy that sends x-rays directly to the tumor using smaller doses over several days and may cause less damage to normal tissue. Drugs, such as nelfinavir mesylate, may make tumor cells more sensitive to radiation therapy. Giving combination chemotherapy with or without oregovomab followed by SBRT and nelfinavir mesylate may kill more tumor cells.
Detailed description public domain (ClinicalTrials.gov)
PRIMARY OBJECTIVES: I. To evaluate the efficacy of neoadjuvant chemotherapy, (gemcitabine \[gemcitabine hydrochloride\], leucovorin \[leucovorin calcium\], fluorouracil \[5-FU\]) with or without oregovomab, followed by hypofractionated stereotactic radiotherapy (SRT) concurrently with nelfinavir (nelfinavir mesylate) in patients with locally advanced pancreatic cancer that is cancer antigen (CA)125 positive (\>= 10) or CA125 negative (\< 10). SECONDARY OBJECTIVES: I. To assess the safety of neoadjuvant chemotherapy, (gemcitabine, leucovorin, 5-FU) with or without oregovomab, followed by SRT concurrently with nelfinavir in patients with locally advanced pancreatic cancer that is CA125 positive (\>= 10) or CA125 negative (\< 10). II. To assess the cellular and humoral immune responses to active immunotherapy with oregovomab/monoclonal antibody in patients with pancreas cancer with CA125 level greater than 10 undergoing chemotherapy and radiation treatments. TERTIARY OBJECTIVES: I. To evaluate tumor and organ motion with 4-dimensional (4D) computed tomography (CT) and respiratory gating system. II. To evaluate the effect of tumor/organ motion on the dosimetry, local control and survival. III. To evaluate inter- and intra-fractional target motion with Calypso system. OUTLINE: CHEMOTHERAPY: Patients receive gemcitabine hydrochloride intravenously (IV), leucovorin calcium IV over 30 minutes, and fluorouracil IV over 24 hours on days 1 and 8. Treatment repeats every 3 weeks for 7 courses. IMMUNOTHERAPY: Patients with CA125 level \>= 10 receive oregovomab IV over 15-30 minutes on day 15. Treatment repeats every 3 weeks for 3 courses (weeks 1, 4, 7) and post- radiation therapy for 1 course (week 14). Patients may receive an additional 3 courses concurrently with chemotherapy upon recovery from surgery based on CA125 level. Patients also receive nelfinavir mesylate orally (PO) twice daily (BID) for 5 weeks beginning on day 15 of week 9. STEREOTACTIC RADIATION THERAPY: Beginning in week 11, patients undergo SBRT in 5 fractions over 5 consecutive days. Upon completion of radiation therapy, patients resume nelfinavir mesylate for 14 days (week 12-13). Patients without metastasis and with resectable disease undergo surgery in week 17-18. After completion of study treatment, patients are followed up every 3 months for 1 year, every 4 months for 1 year, and then every 6 months thereafter.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Number of Participants With Progressive Disease, [Up to 4 months]. Count Of Participants, Participants. Treatment (Chemotherapy, Oregovomab, SBRT, Surgery) (n=10): 2.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Distant Failure-free Survival [Date of administration study drug to the date of first appearance of tumor lesions by imaging, or death, assessed up to 5 years]. Median, months (95% Confidence Interval). Treatment (Chemotherapy, Oregovomab, SBRT, Surgery) (n=11): 11 (7 to 15).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Overall Survival [Date of first of study drug to the date of death, assessed up to 5 years]. Median, months (95% Confidence Interval). Treatment (Chemotherapy, Oregovomab, SBRT, Surgery) (n=11): 14.4 (12 to 18).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Surgical Complete Resection (Negative Margin) Rate [Up to week 18]. Count Of Participants, Participants. Treatment (Chemotherapy, Oregovomab, SBRT, Surgery) (n=10): 4.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Tumor Response Rate, Evaluated on the Pathology Specimen [Up to week 18]. Count Of Participants, Participants. Pathologic poor response: Treatment (Chemotherapy, Oregovomab, SBRT, Surgery) (n=4): 2. Pathologic intermediate response: Treatment (Chemotherapy, Oregovomab, SBRT, Surgery) (n=4): 1. Pathologic good response: Treatment (Chemotherapy, Oregovomab, SBRT, Surgery) (n=4): 1.